Frevecitinib is under clinical development by Kinaset Therapeutics and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Frevecitinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Frevecitinib overview
Frevecitinib (KN-002) is under development for the treatment of severe inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD) and other unspecified disease. It is a small molecule administered by inhalation. The drug candidate is a selective pan-JAK inhibitor. It act by targeting JAK1, JAK2, JAK3 and tyrosine kinase 2
Kinaset Therapeutics overview
Kinaset Therapeutics is a biopharmaceutical company that develops inhaled respiratory disease therapeutics. It focuses on the development of its lead clinical candidate, KN-002, a novel and non-invasive anti-inflammatory treatment for patients with severe asthma. Kinaset Therapeutics’s product, KN-002, is formulated as a dry powder for inhalation, targeting direct delivery to the site of inflammation in the lungs. The company’s products are used in the healthcare industry for patients suffering from severe asthma and potentially other respiratory diseases such as chronic obstructive pulmonary disease (COPD). Kinaset Therapeutics is headquartered in Boston, Massachusetts, the US.
For a complete picture of Frevecitinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
